ASCO 2022 Conference Coverage


 

ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo in 1L mNSCLC: AE Management in POSEIDON Trial

60 views
June 23, 2022
Comments 0
Login to view comments. Click here to Login